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Abstract
A male child, who presented at the age of 3.5 years with acute renal failure, was diagnosed as having partial deficiency of
hypoxanthine-guanine phosphoribosyltransferase (HPRT; EC 2.4.2.8). The underlying HPRT mutation was unique in that
the specific activity of HPRT in erythrocyte and in fibroblast lysates was normal, but the rate of uptake of hypoxanthine into
nucleotides of intact cultured fibroblasts was markedly reduced (23% of normal). The low functioning of HPRT in the intact
fibroblasts was associated with decreased utilization of endogenously generated hypoxanthine and with decreased utilization
of the cosubstrate 5-phosphoribosyl-1-pyrophosphate (PRPP). The non-utilized hypoxanthine was excreted into the
incubation medium. The accumulation of PRPP was indicated by the 2.3-fold increase in the rate of uptake of adenine into
intact cell nucleotides and by the 7.5-fold enhancement of the rate of de novo purine synthesis. Kinetic studies of HPRT
activity in fibroblast lysates revealed reduced affinity of the enzyme for PRPP (apparent Km 500 WM in comparison to 25 WM
in control lysates), manifested in low activity at low (physiological), but not at high PRPP concentrations. The apparent Km
for hypoxanthine was normal (23 WM in comparison to 14.2 WM in control lysates). With allopurinol treatment, our patient
has had no problems since presentation, and is developing normally at 5 years of age. ß 2000 Elsevier Science B.V. All
rights reserved.
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1. Introduction
Hypoxanthine-guanine phosphoribosyltransferase
(HPRT; EC 2.4.2.8) catalyzes the salvage synthesis
of IMP and GMP from the purine bases hypoxan-
thine and guanine, respectively, utilizing 5-phospho-
ribosyl-1-pyrophosphate (PRPP) as cosubstrate. Vir-
tually complete de¢ciency of HPRT activity is
associated with the Lesch-Nyhan syndrome (LNS)
[1,2] whereas partial de¢ciency is associated with
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the Kelley-Seegmiller syndrome (KSS) [3,4]. LNS is
characterized by abnormal metabolic and neurolog-
ical manifestations [1,4]. Metabolically it is associ-
ated with excessive purine production, manifested
mainly in urolithiasis and uric acid nephropathy.
Neurologically, it is associated with compulsive
self-mutilation, choreoathetosis, spasticity and devel-
opmental retardation. In contrast, KSS is usually
associated only with the clinical manifestations of
excessive purine production, the metabolic conse-
quence of HPRT de¢ciency [3,4]. Renal stones, uric
acid nephropathy and renal obstruction are often the
presenting symptoms of KSS, but rarely of LNS.
After puberty, the hyperuricemia in KSS may cause
gout. Intermediate degrees of enzyme de¢ciency are
associated with varying degrees of the above mani-
festations [5]. The excessive purine production in
HPRT de¢ciency is attributed to the accumulation
of PRPP, the cosubstrate for HPRT, which is a limit-
ing substrate for purine synthesis by the de novo
pathway [6,7].
The laboratory diagnosis of HPRT de¢ciency is
obtained usually by assay of the speci¢c activity of
the enzyme in erythrocyte lysates. In LNS no HPRT
activity can be detected, whereas in KSS it usually
ranges from 0.01 to 15% of normal [8]. The speci¢c
activity of HPRT in hemolysates, measured at opti-
mal conditions of substrate concentrations, cannot
be taken to re£ect correctly the actual, physiological
activity of the enzyme in the intact tissues of HPRT-
de¢cient patients. Moreover, it is possible that some
HPRT variants underlying LNS and KSS, rare as
they may be, would be manifested only at the phys-
iological conditions prevailing in the cells. The fol-
lowing is the report of the biochemical features of a
boy with KSS due to a mutation of this type. The
altered HPRT exhibited normal speci¢c activity in
erythrocyte and ¢broblast lysates. The decreased ac-
tivity of the enzyme in vivo could be detected when
the functioning of HPRT in the patient’s tissues was
assessed by study of hypoxanthine uptake into nu-
cleotides of intact ¢broblasts.
2. Clinical history
Patient D.Z. is a 4.5 year old boy, born to non-
consanguineous parents of Jewish Iraqi/Iranian ori-
gin. His mother and two sisters are healthy and his
father su¡ers from gout. He was admitted to the
hospital at the age of 3.5 years, twice within
1 month, with acute renal failure, associating throat
streptococcal infection and fever. Further studies re-
vealed severe hyperuricemia (1249 WM) and hyper-
uricosuria of 7 mmol/day/1.73 m2, which is markedly
elevated for age, even when corrected for 100 ml
GFR (0.25 mmol/100 ml GFR; normal 6 0.03
mmol) [9,10]. Diagnosis of acute renal failure due
to uric acid nephropathy was made. His treatment
included rehydration, alkalinization of urine and al-
lopurinol with normalization of kidney function
within 1 week.
The marked hyperuricosuria indicated excessive
production of uric acid, but all known causes of
acquired hyperuricosuric conditions were ruled out.
Erythrocyte HPRT activity, determined on two oc-
casions, did not di¡er from that in control erythro-
cytes. Thereafter, skin biopsies for ¢broblast cultures
were obtained for a thorough investigation of purine
metabolism.
3. Materials and methods
3.1. Red cell lysates and ¢broblast cultures
All samples from human subjects were obtained
according to protocols approved by the Review
Board of the Rabin Medical Center, with the in-
formed consent of the parents of the patient. Red
cells were separated from heparinized venous blood
and hemolysates prepared as previously described
[11]. Fibroblast cultures from skin biopsies were pre-
pared as previously described [12]. For study of en-
zyme activity, cells of con£uent cultures were har-
vested following short trypsinization, washed in
saline and subjected to three cycles of freezing and
thawing. Cell debris were removed by centrifugation
at 12 000 rpm, at 4‡C.
3.2. Enzyme assays
HPRT and adenine phosphoribosyltransferase
(APRT; EC 2.4.2.7) were assayed radiochemically,
as described before [11]. Protein concentration was
determined according to Bradford [13].
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3.3. Enzyme kinetics
Apparent Km and Vmax values for HPRT were
calculated using Lineweaver-Burk plots and linear
regression analysis. For the determination of the ap-
parent Km for PRPP, its concentration was modi¢ed
to range from 20 WM to 1 mM (50 WM to 1 mM for
the propositus). For the determination of the ap-
parent Km for hypoxanthine, its concentration was
modi¢ed to range from 5 WM to 500 WM.
3.4. Incorporation of purine bases into nucleotides in
intact ¢broblasts
Monolayer ¢broblast cultures in 90 mm dishes
were incubated for 15 min at 37‡C with 5 ml fresh
serum-free culture medium, containing 8 WM of the
labeled purine base. Following incubation, the cul-
ture medium was discarded and the cells were
washed twice with cold saline. Purine nucleotides in
the ¢broblasts were extracted in 0.5 ml of 1 M
perchloric acid and separated from the correspond-
ing purine bases by chromatography on microcrys-
talline cellulose [11], scraped o¡ and counted.
3.5. Measurement of purine synthesis de novo
The rate of purine nucleotide synthesis de novo
was gauged in intact ¢broblasts in culture, by meas-
uring the rate of incorporation of precursor
[14C]formate into cellular purines [12]. Monolayer
cultures in 90 mm culture dishes were incubated for
2 h at 37‡C with 10 WCi sodium [14C]formate (Amer-
sham, Buckinghamshire, UK). After incubation, the
culture media were removed and the cells washed
with cold saline. Total cellular purines were subjected
to hydrolysis in 1 M perchloric acid, at 100‡C for 1 h.
The resulting free purine bases were then precipitated
as purine-silver complexes and the content of label
determined [12].
3.6. Quanti¢cation of hypoxanthine
Hypoxanthine in the culture media was determined
employing HPLC methodology. 0.9 ml of the growth
medium was extracted with 0.1 ml of 10 M perchloric
acid. Two minutes later, the extract was neutralized
with 0.5 ml of a solution of 0.5 M KHCO3 in 1.5 M
KOH and subjected to centrifugation (12 000 rpm,
15 min at 4‡C). Hypoxanthine in the extract was
separated from other purines on Lichrosorb RP-18
columns (Merck, Darmstadt, Germany), using a lin-
ear gradient made from 10 mM KH2PO4, pH 5.3,
and 80% methanol/H2O, for a 30 min period, with
0^25% of the 80% methanol solution, at a £ow rate
of 1.5 ml/min [14]. The HPLC system employed was
Varian 9010 Solvent Delivery System, with Varian
9050 Variable Wavelength Detector set at 254 mW,
and with computerized integrator.
4. Results
4.1. Activity of HPRT and APRT in hemolysates
HPRT and APRT activities were determined in
hemolysates prepared from two di¡erent blood sam-
ples obtained from the patient. HPRT activity was
found to be normal (1.55 and 1.36 nmol/min per mg
cell protein; control value obtained for three control
blood samples was 1.3 þ 0.1 nmol/min per mg cell
protein). On the other hand, APRT activity in the
patient’s hemolysates was elevated, being more than
2-fold the control activity (0.63 and 0.49 nmol/min
per mg cell protein; control value obtained for three
blood samples was 0.24 þ 0.036 nmol/min per mg cell
protein (P6 0.01)).
4.2. Activity of HPRT and APRT in ¢broblast lysates
In the patient’s ¢broblast lysates, HPRT was
78.7% and APRT was 130% of the control mean
values, respectively, both within the control range.
However, the ratio HPRT/APRT was signi¢cantly
lower (P6 0.01) in the ¢broblast lysates of the pa-
tient (Table 1).
4.3. Incorporation of hypoxanthine into nucleotides in
intact cultured ¢broblasts
The rate of incorporation of hypoxanthine into
nucleotides in intact cultured ¢broblasts from patient
D.Z. was 23% of normal and that of adenine 2.3-fold
of normal (for both P6 0.01). In the cells of the
mother, the rate of incorporation of hypoxanthine
was normal, but that of adenine was accelerated sig-
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ni¢cantly (P6 0.05). The ratio of uptake hypoxan-
thine/adenine was signi¢cantly lower (P6 0.01) in
the cells of the mother and of the patient (Table 1).
4.4. Rate of de novo purine synthesis in cultured
¢broblasts
The rate of de novo purine synthesis in intact ¢-
broblasts was gauged by the rate of incorporation of
the labeled precursor formate into cellular purines.
In the cells of patient D.Z. the rate of incorporation
was accelerated 7.5-fold and in his mother’s cells by
5.5-fold, but in the father’s cells the rate of purine
synthesis was normal (Table 1).
4.5. Excretion of hypoxanthine from cultured
¢broblasts
Following incubation for 3 days, the media of the
¢broblast cultures of the patient contained about
10-fold the amount of hypoxanthine in the media
of the control cells (P6 0.001). A signi¢cant
(P6 0.05) 5.5-fold elevation in hypoxanthine excre-
tion was also found in the media of the mother’s
cells, but not in that of the father (Fig. 1).
4.6. Kinetic characterization of mutant HPRT
Kinetic studies of HPRT activity in ¢broblast ly-
sates from patient D.Z. revealed decreased a⁄nity of
the enzyme for PRPP. The apparent Km calculated
from the double reciprocal plot was 500 WM, in com-
parison to 25 WM in the control cells (Fig. 2). In
contrast, the Vmax values of the normal and mutant
enzyme were very close, 139 and 125 nmol/h per mg
cell protein, respectively. Thus, the decreased a⁄nity
of HPRT to PRPP was manifested in decreased ac-
tivity of the enzyme only at low (physiological)
PRPP concentrations. The ratio of activity of the
mutant to normal enzyme increased 7-fold with ele-
vation of PRPP concentration, from about 0.1 at
50 WM to about 0.7 at 1 mM (the activity of
HPRT at 1 mM PRPP was within the normal limits
when compared to control lysates; Table 1). HPRT
activity in dependence on PRPP concentration, in
Fig. 1. Change in the culture medium content of hypoxanthine
by incubation with ¢broblast cultures for 72 h. The medium
purine content was determined as described in Section 3. The
baseline content of hypoxanthine in the fresh medium was 12
nmol/dish (in 5 ml). This content was subtracted from the re-
spective values measured in the medium following incubation
for 72 h.
Table 1
Parameters of purine metabolism in cultured ¢broblasts
Parameter Control Father Mother Propositus
Enzyme activity (nmol/min per mg cell protein)
HPRT 2.12 þ 0.89 (4) 2.70 þ 1.41 (4) 2.95 þ 1.43 (4) 1.67 þ 0.57 (4)
APRT 5.42 þ 1.22 (4) 5.10 þ 1.47 (4) 5.27 þ 0.33 (4) 7.05 þ 1.20 (4)
HPRT/APRT 0.38 þ 0.08 (4) 0.52 þ 0.19 (4) 0.55 þ 0.27 (4) 0.24 þ 0.10 (4)**
Uptake of purine bases into nucleotides (nmol/15 min per mg cell protein)
Hypoxanthine 3.0 þ 1.2 (7) 4.3 þ 3.5 (5) 1.9 þ 2.3 (5) 0.7 þ 0.3 (7)**
Adenine 3.9 þ 1.2 (7) 4.8 þ 1.7 (5) 5.9 þ 2.4 (5)* 9.1 þ 2.7 (7)**
Hypoxanthine/adenine 0.89 þ 0.56 (7) 0.89 þ 0.56 (5) 0.55 þ 0.48 (5)** 0.07 þ 0.03 (7)**
De novo purine synthesis ([14C]formate incorporation; dpm/2 h per mg cell protein)
25 738 þ 8 997 (4) 9 132 (2) 141 780 (2)** 191 780 þ 83 993 (3)**
Values represent mean þ S.D. Numbers in parentheses represent number of determinations, each performed in duplicate.
*P6 0.05; **P6 0.01, by Student’s t-test (paired).
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¢broblast lysates from the mother, exhibited an in-
termediate curve between the control and mutant
enzymes (Fig. 2). The mutant HPRT exhibited nor-
mal apparent Km for hypoxanthine (23 WM in com-
parison to 14 WM in the control cells, 13 WM in the
mother’s cells and 43 WM in the father’s cells).
5. Discussion
Patient D.Z. presented with acute renal failure due
to hyperuricosuria. In absence of evidence for causes
of acquired hyperuricosuric conditions, the purine
overproduction was suggestive of inherited enzyme
abnormality. HPRT de¢ciency is the most common
defect associated with purine overproduction and in
absence of neurological manifestations, the presumed
diagnosis was of partial HPRT de¢ciency, i.e. KSS
[3,4]. However, this diagnosis could not be con¢rmed
by the standard assay of the speci¢c activity of
HPRT, which was found to be within the normal
range in both erythrocyte and ¢broblast lysates (Ta-
ble 1). The presumed diagnosis of KSS was sup-
ported, however, by the ¢nding of increased activity
of APRT in the erythrocyte lysates. Elevated eryth-
rocyte APRT activity is a common ¢nding in HPRT
de¢ciency [4], attributed to stabilization of the en-
zyme by the elevated PRPP concentration, resulting
from HPRT de¢ciency [15]. Additional support for
presence of KSS was the ¢nding of the low ratio
HPRT/APRT in the ¢broblast lysates of the patient
(Table 1).
The ¢rst direct proof for HPRT de¢ciency in pa-
tient D.Z. was provided by the demonstration of a
markedly lower rate of incorporation of hypoxan-
thine into the nucleotides in intact ¢broblasts (Table
1). Of all tests available, the determination of the
rate of uptake of hypoxanthine into nucleotides in
intact cultured skin ¢broblasts was demonstrated to
re£ect best the actual functioning of HPRT in the
intact tissue, under physiological conditions [16]. Ac-
cordingly, this test is expected to detect all disease-
causing HPRT variants. Classical LNS is character-
ized by uptake of 0.2^1.4% of normal, whereas KSS
by uptake of 8^62% of normal [16]. Indeed, by this
test, our patient, exhibiting 23% of normal uptake of
hypoxanthine, could be diagnosed to be a¡ected with
KSS. In accordance with low functioning of HPRT,
the cells of the patient exhibited decreased reutiliza-
tion of endogenously generated hypoxanthine and of
Fig. 2. Double reciprocal plots of initial velocity of HPRT activity from ¢broblast lysates against PRPP (A) and against hypoxanthine
(B) concentrations. b, control enzyme; F, mutant enzyme; R, mother’s cells ; 8, father’s cells. V is expressed in nmol/mg of
protein/h.
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PRPP, the two substrates of HPRT. The decreased
reutilization of hypoxanthine was indicated by the
¢nding of the higher hypoxanthine content in the
media of the cultured ¢broblasts (Fig. 1). The de-
creased consumption of PRPP resulted in its accu-
mulation, manifested in increased metabolic avail-
ability of PRPP. This was indicated by the ¢nding
of the 2.3-fold increase in the rate of adenine incor-
poration into nucleotides and by the 7.5-fold accel-
eration of the rate of de novo purine synthesis in our
patient’s cells (Table 1). These two pathways have
been demonstrated to depend on PRPP availability
[6,7,12]. Although not studied, HPRT functioning is
probably low also in intact erythrocytes of the pa-
tient. This may be assumed in view of the ¢nding of
the increased speci¢c activity of APRT in the eryth-
rocyte lysates, re£ecting accumulation of PRPP (see
above).
Kinetic characterization of the HPRT variant in
¢broblast lysates from patient D.Z. indicated that
the decreased activity of HPRT in the intact ¢bro-
blasts is due to decreased a⁄nity of the enzyme to
substrate PRPP (20-fold increased apparent Km for
this substrate), but not to hypoxanthine (Fig. 2). The
control apparent Km value of HPRT for PRPP ob-
tained in our laboratory is markedly lower than that
reported for puri¢ed human HPRT, ranging from
240 to 390 WM [17,18]. This discrepancy probably
re£ects the speci¢c conditions of the assay employed
in our laboratory. An even lower value, of 6.8 þ 0.6
WM, was reported for the control hemolysates
studied by Lightfoot et al. [19]. Other variants of
HPRT with decreased a⁄nity for PRPP were re-
ported [20,21]. However, unlike our patient, the cases
reported by them were typical in that the speci¢c
activity of HPRT in erythrocyte lysates was low.
Several other mutant HPRT enzymes were reported,
which unlike our mutant enzyme, exhibited increased
apparent Km for both PRPP and hypoxanthine
[19,22,23]. Also in these mutations, HPRT activity
in hemolysates was typically low. To the best of
our knowledge, only one case has been reported pre-
viously of HPRT de¢ciency, without a decreased spe-
ci¢c activity of the enzyme in erythrocyte and ¢bro-
blast lysates [24]. In that case, the enzyme de¢ciency
was diagnosed by study of intact ¢broblasts, which
exhibited characteristic properties of HPRT de¢-
ciency, including growth resistance to 8-azaguanine,
inability to grow in presence of aminopterin and in-
creased sensitivity to inhibition of de novo purine
synthesis by adenine. No attempt was made to clarify
the kinetic nature of that mutation. An additional,
somewhat similar case of KSS was reported, in
whom HPRT activity in peripheral leukocytes and
cultured ¢broblasts was normal, but erythrocyte
HPRT activity was about 30% of normal [25]. In
this case the mutant HPRT exhibited increased sen-
sitivity to product inhibition.
The results of this study, as well as those of the
other rare case reviewed above [24,25], may be taken
to suggest that the diagnosis of HPRT de¢ciency,
virtually complete as in LNS, or partial as in KSS,
cannot be ruled out on the basis of the determination
of the speci¢c activity of the enzyme in red cell or
¢broblast lysates. The results support the previous
observation [16] that determination of uptake of hy-
poxanthine into intact ¢broblasts (and probably also
erythrocytes) is a better and more reliable tool for
diagnosis of HPRT de¢ciency.
In accordance with the X-linked pattern of inher-
itance of HPRT de¢ciency, the ¢broblasts of the
mother, but not of the father, exhibited some degree
of the abnormalities in purine metabolism, that were
found to characterize her son’s cells. These included
increased availability of PRPP, decreased ratio of
hypoxanthine/adenine uptake and enhanced rate of
purine synthesis de novo (Table 1), increased excre-
tion of hypoxanthine from ¢broblasts into the cul-
ture medium (Fig. 1) and decreased a⁄nity of HPRT
for PRPP (Fig. 2).
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